In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
The above has not deterred an industry that is known for its innovation, and resilience, but mostly for the strength of its science. For pharma and biopharma firms – focused on cell and gene therapies, immune-oncology, or pioneering CNS breakthroughs – the focus will now be on embracing digitalization, navigating a changing regulatory and financial landscape, and tackling health inequalities. To support those breakthroughs, the CDMO, CMO, CRO, and services segment continued to strengthen in 2022.
In that context, Global Business Reports offers analysis derived from over 80 interviews with the industry’s most insightful, thought-provoking, and authoritative executives across the life sciences value chain, spanning 19 US states, and with firms from three continents with large footprints in America. Importantly, the report features GBR’s assessment of the trends that are likely to drive the industry in the coming months.